CD8A and cancer: Genetic depletion or inhibition of PIKFYVE with either apilimod or ESK981 enhanced the antigen presentation ability of cancer cells through MHC-I surface expression leading to improved CD8+ T-lymphocyte mobilization and cancer cell killing in vitro and in vivo [85].